Search

Displaying results 2021 - 2030 of 9314 in total
  1. Drug

    Mangafodipir

    go.drugbank.com/drugs/DB06796
    ApprovedInvestigationalWithdrawn

    The contrast agent is present as mangafodipir trisodium marketed under the name Teslascan. … Teslascan has been removed from the Drug Product List by FDA in 2003, and withdrawn from the European market in 2012.

  2. Drug

    Acoramidis

    go.drugbank.com/drugs/DB17999
    ApprovedInvestigational

    [L51958] Similar to the previously developed [tafamidis], acoramidis is used to stabilize TTR in its tetrameric form, preventing the formation of amyloidogenic monomers and the progression of amyloidosis … [A264808] It was brought to market by BridgeBio Pharma and approved by the FDA in November 2024 to reduce negative cardiovascular outcomes in patients with cardiomyopathy caused by TTR amyloidosis.

  3. Drug

    Palopegteriparatide

    go.drugbank.com/drugs/DB18676
    ApprovedInvestigational

    [L51134] PTH(1-34) contains the N-terminal part of the endogenous PTH molecule. … [L51134] Palopegteriparatide was first approved by the EMA on November 17, 2023, for the treatment of hyperparathyroidism.[L51134] On August 8, 2024, palopegteriparatide was also approved by the FDA.

    Synonyms: Human parathyroid hormone (PTH) synthetic peptide fragment (1-34), conjugated at the N-terminal amino group via a cleavable linker to O-methylpolyethylene glycol (2 x 20 kDa mPEG); 2-methylalanyl-(1-34
  4. Drug

    Meglumine

    go.drugbank.com/drugs/DB09415
    ApprovedInvestigational

    Mixtures: UROGRAFIN %76 IV ENJEKSIYON VE INFUZYON ICIN COZELTI, 100 ML, UROGRAFIN %76 IV ENJEKSIYON VE INFUZYON ICIN COZELTI, 50 ML
  5. Drug

    Trametinib

    go.drugbank.com/drugs/DB08911
    ApprovedInvestigational

    [A258298,A258293] It was first approved by the FDA in May 2013 for the treatment of melanoma. … [A258298] It was later approved by Health Canada on July 18, 2013 [L45588] and by the European Commission on June 30, 2014.

  6. Drug

    Polythiazide

    go.drugbank.com/drugs/DB01324
    Approved

    A thiazide diuretic with actions and uses similar to those of hydrochlorothiazide. (From Martindale, The Extra Pharmacopoeia, 30th ed, p826)

  7. Drug

    (S)-camphor

    go.drugbank.com/drugs/DB11345
    Approved

    [DB01744] is isolated from the wood of the camphor laurel tree, _Cinnamomum camphora_, and had a long history of medicinal use. … Camphor is a major active ingredient in over-the-counter balms and liniments supplied as topical analgesics by causing sensitization to heat and coolness to relieve minor muscle and joint pain [A33086]

  8. Drug

    Avelumab

    go.drugbank.com/drugs/DB11945
    ApprovedInvestigational

    [A261496] Avelumab was first approved by the FDA on March 23, 2017. … Avelumab is a human IgG1 lambda monoclonal antibody that binds programmed cell death ligand-1 (PD-L1) to block its interaction with its receptors found on T cells and antigen-presenting cells.

  9. Drug

    Mephenytoin

    go.drugbank.com/drugs/DB00532
    ApprovedWithdrawn

    Mephenytoin is used for the treatment of refractory partial epilepsy. Mephenytoin is a solid. This compound belongs to the phenylhydantoins. … Mephenytoin is known to target sodium channel protein type 5 subunit alpha.

  10. Drug

    Sipavibart

    go.drugbank.com/drugs/DB21908
    ApprovedInvestigational

    [A274098] It works by binding to the SARS-CoV-2 spike protein receptor binding domain (RBD), neutralize the virus and preventing its entry into the host cell. … [A274088] Sipavibart is approved for the pre-exposure prophylaxis treatment of COVID-19 in immunocompromised patients.[L53418]

    Synonyms: Gamma1 heavy chain Homo sapiens (1-455) [VH (Homo sapiens IGHV3-9*01 (94.9%) -(IGHD) -IGHJ1*01 (90.9%) L123>T (120), CDR-IMGT [8.8.18] (26-33.51-58.97-114)) (1-125) -Homo sapiens IGHG1*03, G1m3, nG1m1